ES2754271T3 - Polipéptidos escindibles por enteroquinasa - Google Patents

Polipéptidos escindibles por enteroquinasa Download PDF

Info

Publication number
ES2754271T3
ES2754271T3 ES14827189T ES14827189T ES2754271T3 ES 2754271 T3 ES2754271 T3 ES 2754271T3 ES 14827189 T ES14827189 T ES 14827189T ES 14827189 T ES14827189 T ES 14827189T ES 2754271 T3 ES2754271 T3 ES 2754271T3
Authority
ES
Spain
Prior art keywords
polypeptide
enterokinase
cleavable fusion
amino acid
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14827189T
Other languages
English (en)
Spanish (es)
Inventor
Kjeld Olesen
Jakob Brandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2754271T3 publication Critical patent/ES2754271T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21009—Enteropeptidase (3.4.21.9), i.e. enterokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES14827189T 2013-12-17 2014-12-17 Polipéptidos escindibles por enteroquinasa Active ES2754271T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197732 2013-12-17
PCT/EP2014/078165 WO2015091613A1 (fr) 2013-12-17 2014-12-17 Polypeptides pouvant être clivées par une entérokinase

Publications (1)

Publication Number Publication Date
ES2754271T3 true ES2754271T3 (es) 2020-04-16

Family

ID=49765411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14827189T Active ES2754271T3 (es) 2013-12-17 2014-12-17 Polipéptidos escindibles por enteroquinasa

Country Status (6)

Country Link
US (1) US9982287B2 (fr)
EP (1) EP3083701B1 (fr)
JP (2) JP6200087B2 (fr)
CN (1) CN105829350B (fr)
ES (1) ES2754271T3 (fr)
WO (1) WO2015091613A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2754271T3 (es) * 2013-12-17 2020-04-16 Novo Nordisk As Polipéptidos escindibles por enteroquinasa
EP3757119A1 (fr) * 2015-11-16 2020-12-30 Ubiprotein, Corp. Procédé permettant d'étendre la demi-vie d'une protéine
US11230585B2 (en) * 2016-09-06 2022-01-25 Chemical & Biopharmaceutical Laboratories Of Patra Proinsulin derivatives
WO2018083335A1 (fr) * 2016-11-07 2018-05-11 Novo Nordisk A/S Esters à dchbs actif de composés peg et leur utilisation
CN117467649A (zh) * 2022-10-31 2024-01-30 杭州先为达生物科技股份有限公司 高特异性肠激酶酶切方法及乙醇在提高肠激酶酶切特异性中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
AU6855901A (en) 2000-06-19 2002-01-02 Dyax Corp Novel enterokinase cleavage sequences
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2006067198A2 (fr) * 2004-12-22 2006-06-29 Direvo Biotech Ag Nouvelles entites biologiques et utilisation ciblee de celles-ci
EP2076527B1 (fr) * 2006-10-13 2014-12-10 Novo Nordisk Health Care AG Enzymes de maturation fusionnées à des marqueurs de protéines basiques
US9238010B2 (en) * 2011-01-13 2016-01-19 The Trustees Of The University Of Pennsylvania Vesicles and nanostructures from recombinant proteins
WO2012112434A1 (fr) * 2011-02-14 2012-08-23 Allergan, Inc. Procédé permettant d'inhiber la formation de vaisseaux sanguins aberrants au moyen d'endopeptidases reciblées
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
WO2012112422A1 (fr) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibition de la formation aberrante de vaisseaux sanguins à l'aide d'endopeptidases reciblées sur la facteur de croissance
JP6138151B2 (ja) * 2011-12-23 2017-05-31 ノヴォ ノルディスク アー／エス 修飾されたエンテロキナーゼ軽鎖
ES2754271T3 (es) * 2013-12-17 2020-04-16 Novo Nordisk As Polipéptidos escindibles por enteroquinasa

Also Published As

Publication number Publication date
WO2015091613A1 (fr) 2015-06-25
US20160319321A1 (en) 2016-11-03
CN105829350B (zh) 2021-01-08
JP6200087B2 (ja) 2017-09-20
US9982287B2 (en) 2018-05-29
EP3083701B1 (fr) 2019-08-07
EP3083701A1 (fr) 2016-10-26
CN105829350A (zh) 2016-08-03
JP2017184764A (ja) 2017-10-12
JP2016537974A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
ES2754271T3 (es) Polipéptidos escindibles por enteroquinasa
ES2661404T3 (es) Métodos para la expresión de péptidos y proteínas
US7544512B2 (en) Method of producing insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs
Aboye et al. Efficient one-pot cyclization/folding of rhesus θ-defensin-1 (RTD-1)
Su et al. High-level expression and purification of human epidermal growth factor with SUMO fusion in Escherichia coli
US9611466B2 (en) Modified enterokinase light chain
Razali et al. Soluble expression and catalytic properties of codon-optimized recombinant bromelain from MD2 pineapple in Escherichia coli
Ye et al. An efficient large-scale refolding technique for recovering biologically active recombinant human FGF-21 from inclusion bodies
Sharma et al. Recombinant human epidermal growth factor inclusion body solubilization and refolding at large scale using expanded-bed adsorption chromatography from Escherichia coli
US20160122793A1 (en) Fusion Protease
CN103998606B (zh) 修饰的肠激酶轻链
CA3134167A1 (fr) Proteine de fusion contenant des fragments proteiques fluorescents et utilisations associees
Yuan et al. Improved self-cleaving precipitation tags for efficient column free bioseparations
WO2017118752A1 (fr) Chaîne légère modifiée d'entérokinase et son procédé de préparation
WO2009005140A1 (fr) Dérivé d'enzyme recombinante c-terminal-α-amidée
KR20110086711A (ko) 봉입체 형성 단백질의 제조방법
EP1674567B1 (fr) Procede de clivage de polypeptide mettant en oeuvre un mutant de protease ompt
JP2020513834A (ja) ペプチドの発現および大規模生産
WO2012048856A1 (fr) Proinsuline avec séquence auxiliaire
EP2867250A2 (fr) Proinsuline comprenant une séquence auxiliaire améliorée
WO2012098009A1 (fr) Polypeptide chimérique comprenant une protéine membranaire et un précurseur de l'insuline